Form 4: Arrowhead Pharmaceuticals Director Acquires Shares Through Restricted Stock Units

Michael Perry, a director at Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock through the vesting of restricted stock units.

Summary

• Michael Perry, a director of Arrowhead Pharmaceuticals, acquired 16,733 shares of common stock on December 18, 2024.
• The shares were acquired through the vesting of restricted stock units at a price of $22.99 per share.
• Following the transaction, Mr. Perry directly owns 131,490 shares of Arrowhead Pharmaceuticals common stock.
• The restricted stock units vest in one installment on the first anniversary date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director increasing their stake in the company, which is generally seen as a positive sign. However, it is a routine transaction.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to stock-based compensation for a company director, which is common in the biotechnology industry.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotechnology industry to align the interests of management and shareholders.
• The vesting schedule of one year is fairly standard for restricted stock units.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates confidence from a company director.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Director, Michael Perry, Stock Acquisition, Restricted Stock Units, Share Ownership, SEC Form 4